Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial.

Malouf-Sierra J, Tarantino U, García-Hernández PA, Corradini C, Overgaard S, Stepan JJ, Borris L, Lespessailles E, Frihagen F, Papavasiliou K, Petto H, Aspenberg P, Caeiro JR, Marin F, Marin F

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research26 Jan 2017Cited by 39 (Europe PMC)

PMID28019683DOI10.1002/jbmr.3067PepBankPUB-28019683

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture surgery, teriparatide increased lumbar spine BMD more than risedronate at 78 weeks.
In plain wordsAfter hip fracture surgery, teriparatide increased lower spine bone density more than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at 78 weeks
Study
n = 171
Comparator
Risedronate
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Measurements
Lumbar spine BMD change
11.08%
teriparatide
Lumbar spine BMD change
6.45%
risedronate
Source sentences
Summary
At 78 weeks, BMD increased significantly more with teriparatide compared to risedronate at the LS (+11.08% versus +6.45%; p < 0.001) and FN (+1.96% versus -1.19%; p = 0.003), with no significant between-group difference in TH BMD.
4 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Summary · context
Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks.
Report a problemFND-2801968301
02HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture surgery, teriparatide increased femoral neck BMD more than risedronate at 78 weeks.
In plain wordsAfter hip fracture surgery, teriparatide increased femoral neck bone density more than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD at 78 weeks
Study
n = 171
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Measurements
Femoral neck BMD change
1.96%
teriparatide
Femoral neck BMD change
−1.19%
risedronate
Source sentences
Summary
At 78 weeks, BMD increased significantly more with teriparatide compared to risedronate at the LS (+11.08% versus +6.45%; p < 0.001) and FN (+1.96% versus -1.19%; p = 0.003), with no significant between-group difference in TH BMD.
3 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Report a problemFND-2801968302
03HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture surgery, total hip BMD did not differ significantly between teriparatide and risedronate.
In plain wordsAfter hip fracture surgery, total hip bone density did not differ significantly between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD at 78 weeks
Study
n = 171
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Source sentences
Summary
At 78 weeks, BMD increased significantly more with teriparatide compared to risedronate at the LS (+11.08% versus +6.45%; p < 0.001) and FN (+1.96% versus -1.19%; p = 0.003), with no significant between-group difference in TH BMD.
3 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Report a problemFND-2801968303
04HumanRandomized controlled trialEfficacy outcome
After hip fracture surgery, the timed up-and-go test was faster with teriparatide than risedronate at 6, 12, 18, and 26 weeks.
In plain wordsAfter hip fracture surgery, patients completed the movement test faster with teriparatide than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTimed up-and-go test
Study
n = 171
Comparator
Risedronate
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Measurements
TUG time difference versus risedronate
−3.2 to −5.9 s
teriparatide minus risedronate, 6 to 26 weeks
Source sentences
Summary
Timed up-and-go (TUG) test was significantly faster with teriparatide at 6, 12, 18, and 26 weeks (differences: -3.2 to -5.9 s; p = 0.045 for overall difference).
3 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Report a problemFND-2801968304
05HumanRandomized controlled trialEfficacy outcome
After hip fracture surgery, pain during the movement test was lower with teriparatide than risedronate at 18 weeks, without significant overall difference.
In plain wordsAfter hip fracture surgery, test pain was lower with teriparatide at 18 weeks than risedronate, but the overall difference was not significant.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseHip pain during timed up-and-go
Study
n = 171
Comparator
Risedronate
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Measurements
Hip pain VAS adjusted difference during TUG
−11.3 mm
teriparatide minus risedronate, 18 weeks
Hip pain VAS adjusted difference during TUG
−10 mm
teriparatide minus risedronate, 12 weeks
Hip pain VAS adjusted difference during TUG
−9.3 mm
teriparatide minus risedronate, 26 weeks
Source sentences
Summary
Hip pain during TUG test by 100 mm VAS was significantly lower with teriparatide at 18 weeks (adjusted difference: -11.3 mm, p = 0.033; -10.0 and -9.3 mm at 12 and 26 weeks, respectively; p = 0.079 for overall difference).
3 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Report a problemFND-2801968305
06HumanRandomized controlled trialEfficacy outcome
After hip fracture surgery, other secondary and exploratory outcomes did not differ between teriparatide and risedronate.
In plain wordsAfter hip fracture surgery, other secondary and exploratory outcomes did not differ between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOther secondary and exploratory outcomes
Study
n = 171
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Source sentences
Summary
Other secondary and exploratory outcomes were not different.
3 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Report a problemFND-2801968306
07HumanRandomized controlled trialSafety outcome
After hip fracture surgery, the teriparatide group had two new hip fractures versus seven with risedronate, without a significant difference.
In plain wordsAfter hip fracture surgery, new hip fractures did not differ significantly between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNew hip fractures
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Measurements
New hip fractures
2 fractures
teriparatide
New hip fractures
7 fractures
risedronate
Source sentences
Summary
Teriparatide group showed two new hip fractures versus seven with risedronate (p = 0.171) and more frequent hypercalcemia and hyperuricemia.
3 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Report a problemFND-2801968307
08HumanRandomized controlled trialSafety outcome
After hip fracture surgery, hypercalcemia was more frequent with teriparatide than risedronate.
In plain wordsAfter hip fracture surgery, high blood calcium was more frequent with teriparatide than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHypercalcemia
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Source sentences
Summary
Teriparatide group showed two new hip fractures versus seven with risedronate (p = 0.171) and more frequent hypercalcemia and hyperuricemia.
3 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Report a problemFND-2801968308
09HumanRandomized controlled trialSafety outcome
After hip fracture surgery, hyperuricemia was more frequent with teriparatide than risedronate.
In plain wordsAfter hip fracture surgery, high blood uric acid was more frequent with teriparatide than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHyperuricemia
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Adverse events · Metabolic and weight
Studied dose
20 μg every day · 78 weeksAs given in this study (human).
Source sentences
Summary
Teriparatide group showed two new hip fractures versus seven with risedronate (p = 0.171) and more frequent hypercalcemia and hyperuricemia.
3 context sentences(design, population, supporting numbers)
Summary · context
We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture.
Summary · context
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
Summary · context
Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females).
Report a problemFND-2801968309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.